Vanderbilt’s Robert Coffey Jr., M.D., has received an Outstanding Investigator Award from the National Cancer Institute (NCI) — more than $6.6 million over seven years — to support studies aimed at advancing the diagnosis and treatment of colorectal cancer (CRC), a leading cancer killer.

An international genomic data-sharing consortium has analyzed nearly 19,000 patient genomic records and found that testing of patient tumors for relevant gene mutations often provides a roadmap for the use of effective therapies.

Blood type A was associated with longer ovarian cancer survival in a recent Vanderbilt-led study.

Vanderbilt University Medical Center cancer researcher James Goldenring, M.D., Ph.D., has received a two-year, $200,000 grant from the DeGregorio Family Foundation in Pleasantville, New York, to begin clinical trials of a potential approach for reversing precancerous stomach lesions.

Three Ingram family members are making gifts totaling $20 million to name Vanderbilt University’s newest College Hall in honor of their late father and former Board of Trust member, E. Bronson Ingram.

A study led by Vanderbilt-Ingram Cancer Center (VICC) investigators suggests a drug combination which includes a PDK1 protein blocker may be more effective for breast cancer that has become resistant to cyclin-dependent kinase (CDK4/6) targeted therapy.

A federal task force has changed its recommendation about prostate cancer screening for some older men. The United States Preventive Services Task Force (USPSTF) now recommends that men between the ages of 55 to 69 consult with their physicians about getting routine screening blood tests to detect prostate cancer.